Related Experiment Video

Updated: Mar 28, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.8K

Telavancin (Vibativ). A vancomycin derivative, no more effective but more toxic

    Prescrire International
    |December 22, 2015
    PubMed

    Insights

    Telavancin is not more effective than vancomycin for hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus. This antibiotic has more adverse effects and should not replace standard treatments.

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Critical Care Medicine

    Background:

    • Nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) is often treated with vancomycin, teicoplanin, or linezolid.
    • Telavancin, a vancomycin derivative, is active against MRSA and approved for second-line treatment of nosocomial pneumonia in the EU.
    • Clinical data on telavancin's efficacy in patients resistant to first-line antibiotics are lacking.

    Purpose of the Study:

    • To evaluate the efficacy and safety of telavancin compared to vancomycin for nosocomial pneumonia.
    • To assess telavancin's effectiveness in MRSA infections.
    • To identify potential risks and adverse effects associated with telavancin use.

    Main Methods:

    • Two randomized trials involving 1532 patients with nosocomial pneumonia.
    • Comparison of cure rates between telavancin and vancomycin treatment groups.
    • Analysis of mortality rates and adverse events, including renal impairment and QT prolongation.

    Main Results:

    • Telavancin and vancomycin demonstrated similar cure rates for nosocomial pneumonia, including MRSA cases.
    • Higher mortality rates were observed in the telavancin group, particularly in patients with renal impairment.
    • Telavancin exhibited more renal adverse effects and QT prolongation compared to vancomycin.

    Conclusions:

    • Telavancin offers no demonstrable efficacy advantage over vancomycin for nosocomial pneumonia.
    • Telavancin is associated with a higher risk of adverse events, including nephrotoxicity and mortality.
    • Current evidence does not support the use of telavancin over established antibiotics like vancomycin for MRSA nosocomial pneumonia.

    More Related Videos

    A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically11:28

    A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

    Published on: September 9, 2015

    29.9K
    In Vivo Mouse Model of Spinal Implant Infection08:03

    In Vivo Mouse Model of Spinal Implant Infection

    Published on: June 23, 2020

    2.9K

    Related Concept Videos

    Antimicrobial Effectiveness01:28

    Antimicrobial Effectiveness

    The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
    2.0K
    Inhibitors of Gram-positive Cell Wall Synthesis01:23

    Inhibitors of Gram-positive Cell Wall Synthesis

    Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
    39
    Antibiotic Selection00:57

    Antibiotic Selection

    Overview
    62.1K
    Inhibitors of Bacterial Protein Synthesis01:25

    Inhibitors of Bacterial Protein Synthesis

    Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
    31
    Inhibitors of Bacterial DNA Synthesis01:28

    Inhibitors of Bacterial DNA Synthesis

    Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
    43
    Antifungal Agents01:15

    Antifungal Agents

    Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
    37